X-Zell Revenue and Competitors

X-ZELL is a global med tech start-up specialising in the isolation, digitisation and AI-guided analysis of atypical cells won from small, 8-10mL blood samples. Using a suite of patented and proprietary technologies that can be plugged into a standard pathology lab, X-ZELL's breakthrough came in 2017 when we found a way to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in whole blood. Known to be powerful biomarkers for the early detection of clinically significant cancers, tCEC were long considered ‘undetectable' in clinical routine. X-ZELL overcame that long-standing impasse by fusing next-generation multiplexing with cryo-technology and Artificial Intelligence – empowering scientists to identify a single tCEC among more than 5 billion healthy blood cells and visualise it on screen with never-before-seen clarity. Backed by Y Combinator, international angel investors as well as institutional investors from both Europe and Asia, X-ZELL went on to develop the world's first tCEC-based blood test for the early detection of clinically significant prostate cancer – X-ZELL™ Prostate. In 2018-19, a blinded, prospective clinical study demonstrated that X-ZELL™ Prostate can safely prevent more than 70 per cent of unnecessary biopsies in high-risk prostate cancer patients, paving the way for a new, pain- and risk-free screening paradigm. The first in a series of targeted liquid biopsies, X-ZELL Prostate™ is already approved for sale in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. Headquartered in Singapore, X-ZELL's ambition is to make tCEC-based cancer screening accessible to patients around the globe – accurate, affordable and accessible for all. More in-depth information on www.x-zell.com/blog and via our Twitter handle @XZELLInc